Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.

Tumour necrosis factor (TNF) is a proinflammatory cytokine that is known to regulate inflammation in a number of autoimmune diseases, including multiple sclerosis (MS). Although targeting of TNF in models of MS has been successful, the pathological role of TNF in MS remains unclear due to clinical t...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah K Williams, Olaf Maier, Roman Fischer, Richard Fairless, Sonja Hochmeister, Aleksandar Stojic, Lara Pick, Doreen Haar, Sylvia Musiol, Maria K Storch, Klaus Pfizenmaier, Ricarda Diem
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090117&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850190099213451264
author Sarah K Williams
Olaf Maier
Roman Fischer
Richard Fairless
Sonja Hochmeister
Aleksandar Stojic
Lara Pick
Doreen Haar
Sylvia Musiol
Maria K Storch
Klaus Pfizenmaier
Ricarda Diem
author_facet Sarah K Williams
Olaf Maier
Roman Fischer
Richard Fairless
Sonja Hochmeister
Aleksandar Stojic
Lara Pick
Doreen Haar
Sylvia Musiol
Maria K Storch
Klaus Pfizenmaier
Ricarda Diem
author_sort Sarah K Williams
collection DOAJ
description Tumour necrosis factor (TNF) is a proinflammatory cytokine that is known to regulate inflammation in a number of autoimmune diseases, including multiple sclerosis (MS). Although targeting of TNF in models of MS has been successful, the pathological role of TNF in MS remains unclear due to clinical trials where the non-selective inhibition of TNF resulted in exacerbated disease. Subsequent experiments have indicated that this may have resulted from the divergent effects of the two TNF receptors, TNFR1 and TNFR2. Here we show that the selective targeting of TNFR1 with an antagonistic antibody ameliorates symptoms of the most common animal model of MS, experimental autoimmune encephalomyelitis (EAE), when given following both a prophylactic and therapeutic treatment regime. Our results demonstrate that antagonistic TNFR1-specific antibodies may represent a therapeutic approach for the treatment of MS in the future.
format Article
id doaj-art-d22907a816ca48d2a37e88deabdc6de2
institution OA Journals
issn 1932-6203
language English
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-d22907a816ca48d2a37e88deabdc6de22025-08-20T02:15:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0192e9011710.1371/journal.pone.0090117Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.Sarah K WilliamsOlaf MaierRoman FischerRichard FairlessSonja HochmeisterAleksandar StojicLara PickDoreen HaarSylvia MusiolMaria K StorchKlaus PfizenmaierRicarda DiemTumour necrosis factor (TNF) is a proinflammatory cytokine that is known to regulate inflammation in a number of autoimmune diseases, including multiple sclerosis (MS). Although targeting of TNF in models of MS has been successful, the pathological role of TNF in MS remains unclear due to clinical trials where the non-selective inhibition of TNF resulted in exacerbated disease. Subsequent experiments have indicated that this may have resulted from the divergent effects of the two TNF receptors, TNFR1 and TNFR2. Here we show that the selective targeting of TNFR1 with an antagonistic antibody ameliorates symptoms of the most common animal model of MS, experimental autoimmune encephalomyelitis (EAE), when given following both a prophylactic and therapeutic treatment regime. Our results demonstrate that antagonistic TNFR1-specific antibodies may represent a therapeutic approach for the treatment of MS in the future.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090117&type=printable
spellingShingle Sarah K Williams
Olaf Maier
Roman Fischer
Richard Fairless
Sonja Hochmeister
Aleksandar Stojic
Lara Pick
Doreen Haar
Sylvia Musiol
Maria K Storch
Klaus Pfizenmaier
Ricarda Diem
Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.
PLoS ONE
title Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.
title_full Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.
title_fullStr Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.
title_full_unstemmed Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.
title_short Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.
title_sort antibody mediated inhibition of tnfr1 attenuates disease in a mouse model of multiple sclerosis
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090117&type=printable
work_keys_str_mv AT sarahkwilliams antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis
AT olafmaier antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis
AT romanfischer antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis
AT richardfairless antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis
AT sonjahochmeister antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis
AT aleksandarstojic antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis
AT larapick antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis
AT doreenhaar antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis
AT sylviamusiol antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis
AT mariakstorch antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis
AT klauspfizenmaier antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis
AT ricardadiem antibodymediatedinhibitionoftnfr1attenuatesdiseaseinamousemodelofmultiplesclerosis